Overview

• On May 31, the Delhi High Court granted interim relief to Novo Nordisk, prohibiting the Indian firms from marketing semaglutide domestically.
• Dr. Reddy’s and OneSource started manufacturing semaglutide under December 2024 licences and pledged not to sell the drug in India following the order.
• Both companies reserve the right to export semaglutide to territories where Novo Nordisk holds no patent, a move Novo Nordisk argues violates the Patents Act, 1970.
• Dr. Reddy’s has accused Novo Nordisk of evergreening by asserting that semaglutide was disclosed in an earlier Indian patent to extend market exclusivity.
• The court has scheduled the next hearing for August 19, 2025 to review written statements and further submissions on sales and export issues.